PARTNERSHIP OPPORTUNITIES
In the rapidly evolving landscape of antifibrotic drug development, the 8th Antifibrotic Drug Development Summit stood out as the premier event for uniting leaders across Pulmonology, Hepatology, Rheumatology, Nephrology, Cardiology, and Gastroenterology under one roof. This summit offered an unparalleled platform for your company to position yourself at the forefront of the antifibrotic drug development community.
Converse with highly engaged experts from diverse therapeutic areas and showcase your innovative solutions to the key challenges in fibrosis research. This summit was the definitive forum for cutting-edge research, dynamic discussions, and strategic partnerships, providing an unrivalled platform to elevate your brand and drive the development of transformative, disease-modifying therapeutics. Don’t miss this chance to be part of the industry's leading event.
Download the event guide to learn more about how you can showcase your brand and capitalize on our audience of leading companies with active pipelines in IPF, MASH, systemic sclerosis, kidney fibrosis, cardiac fibrosis, fibrosing IBD, and more.
2024 EVENT GUIDE
What Could the 8th Antifibrotic Drug Development Summit Do for You?
Secure an exhibition booth to drive brand visibility and position your capabilities to developers who are actively seeking new solutions to optimize antifibrotic drug development inefficiencies. Highlight your innovative products and services to an engaged audience of industry leaders.
Enhance business leads and connections by networking one-on-one with key stakeholders during our structured networking sessions. Understand their specific needs and present your solutions to establish valuable connections and drive business growth.
Deliver a compelling presentation to influence the thinking of preclinical, translational, and clinical decision-makers. Share your insights and expertise to help identify promising compounds and drive clinical success in antifibrotic drug development. Let your offerings speak for themselves and leave a lasting impression on the community.
Drug Developers Required Expert Help With:
Preclinical Models: Accurate models that replicate the chronic and progressive nature of fibrotic diseases across various organs. This includes 3D-tissue models, precision-cut human tissue slices, and humanized mouse models.
Biomarker Providers: Advanced biomarkers to indicate the presence, progression, and response to treatment of fibrotic diseases, enabling precise diagnosis and assessment of therapeutic efficacy.
Discovery/AI/Omics Technologies: Innovative technologies such as high-throughput screening (HTS), machine learning, integrative omics approaches, and computational models to enhance understanding of disease mechanisms and optimize drug discovery processes.
Imaging Technologies: High-resolution and functional imaging techniques (MRI, CT, PET, ultrasound) for non-invasive and precise visualization of fibrotic tissue changes over time, supporting the development of effective antifibrotic interventions.
